A fair comparison asks whether the treatment caused the relief

Fair studies compare different shots without telling people which one they got

People often seek care when the hip is having a bad week. The soreness may ease later because of time or rest. Attention during a clinic visit can affect how people report pain too. Even a saline shot, made from sterile salt water, may bring short relief after the visit and joint procedure.

A fair study places people in separate groups. One group gets the treatment being tested. The other gets a different shot, often salt water. People in both groups aren't told which shot they received. The person checking their results also isn't told. That secrecy keeps hopes about one treatment from tilting the answers.

A study without this comparison can show that people felt better. It can't prove which part of their care helped.

Walking, sleep, and dressing show whether relief is large enough to feel

Research often uses a pain form with numbered answers. A small drop in that score may be real on paper. It may still be too small to change your walk or sleep. Useful relief should be clear in an ordinary task you care about.

Time also matters. Relief during the first good weeks may fade later. A useful study checks again after normal activity returns. It also reports any soreness or swelling after the shot.

During a QC Kinetix visit, clinicians can discuss platelet-rich plasma (PRP), a shot made after a patient's blood is drawn, spun into layers, and reduced to the part with more platelets.

The clinic talk should keep knee findings separate from hip findings. It should also cover how long your relief might last.

Sources

1. A meta-analysis of 14 placebo cohorts from 13 Level-1 knee OA injection trials (1,076 patients, KL 1-4) measured what the SALINE arms did. Intra-articular normal saline produced a statistically significant VAS pain improvement at 3 months (MD 12.10) and a larger one at 6 months (MD 16.62), reaching clinically meaningful thresholds. Any uncontrolled report of 'my injection worked' has to clear this bar before it means anything about the injectate.

   Saltzman BM, et al. — The Therapeutic Effect of Intra-articular Normal Saline Injections for Knee Osteoarthritis: A Meta-analysis of Evidence Level 1 Studies.. The American journal of sports medicine, 2017. DOI: 10.1177/0363546516680607.

2. A network meta-analysis in Annals of Internal Medicine showed that placebo treatments in osteoarthritis trials are not equivalent to one another: the delivery route itself changes the response, with intra-articular placebo producing larger effects than oral placebo. This is a structural reason to distrust any comparison of an injected product against a pill, or against no treatment.

   Bannuru RR, et al. — Effectiveness and Implications of Alternative Placebo Treatments: A Systematic Review and Network Meta-analysis of Osteoarthritis Trials.. Annals of internal medicine, 2015. DOI: 10.7326/M15-0623.

3. A Mayo Clinic single-blind placebo-controlled trial used each patient as their own control: 25 patients with BILATERAL knee OA received bone marrow aspirate concentrate in one knee and saline in the other. Pain fell significantly in BOTH knees at 1 week, 3 months and 6 months - and the relief, described by the authors as dramatic, did NOT differ significantly between the BMAC knee and the saline knee. No serious adverse events occurred.

   Shapiro SA, et al. — A Prospective, Single-Blind, Placebo-Controlled Trial of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis.. The American journal of sports medicine, 2017. DOI: 10.1177/0363546516662455.

4. A GRADE-rated systematic review and meta-analysis of 16 randomized trials (807 participants) found that MSC therapy for chronic knee OA pain PROBABLY RESULTS IN LITTLE TO NO DIFFERENCE in pain relief at 3-6 months (WMD -0.74 cm on a 10 cm VAS against a minimally important difference of 1.5 cm) or physical functioning (WMD 2.23 on the SF-36 100-point subscale against a 10-point MID), both moderate certainty; at 12 months pain was again probably little-to-no-different (WMD -0.73 cm). The measured effect is real but sits BELOW the threshold at which a patient would notice it.

   Sadeghirad B, et al. — Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.. Osteoarthritis and cartilage, 2024. DOI: 10.1016/j.joca.2024.04.021.

5. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other.

   Eckstein F, et al. — Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.. Annals of the rheumatic diseases, 2021. DOI: 10.1136/annrheumdis-2020-219181.

6. OA-11, a 56-week phase 3 double-blind placebo-controlled trial, randomized 513 knee OA patients (KL 2-3) to a single intra-articular injection of the Wnt-pathway modulator lorecivivint or vehicle placebo. Lorecivivint MISSED its primary endpoint: 12-week pain NRS change was -2.24 with drug versus -2.49 with placebo (p=0.185), no other endpoint showed a discernible treatment effect, and neither group lost meaningful medial joint space over 52 weeks. Even a purpose-built, well-funded disease-modifying candidate has not beaten a placebo injection.

   Yazici Y, et al. — A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis.. Clinical and experimental rheumatology, 2025. DOI: 10.55563/clinexprheumatol/hjt118.

7. A network meta-analysis restricted to LARGE intra-articular trials (57 RCTs, 22,795 participants, >=100 patients per group) found treatment effects were consistently larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. Excluding high-risk trials, triamcinolone had the highest probability of exceeding the minimal important difference at weeks 2 and 6; hyaluronic acid had no effect on pain (SMD -0.04, 95% CI -0.19 to 0.11) with higher odds of dropouts due to adverse events (OR 2.01) and serious adverse events (OR 1.86) than placebo. Effects of 16 of 18 interventions were smaller than the MID.

   Pereira TV, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis.. Osteoarthritis and Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.

8. A Level-1a systematic review of 87 randomized PRP-for-knee-OA trials (7,925 patients, 8,118 knees) scored them against the 23-item MIBO reporting checklist. The overall MIBO score was 72%, 71% of studies scored below 80%, and reporting was worst on exactly the items that define the product: whole-blood characteristics (20%), platelet recovery rate (22%), PRP analysis (30%), PRP activation (47%). Adherence did not improve after MIBO was published. Much of the PRP literature does not say what was actually injected.

   Nakagawa HF, et al. — Systematic Review of Randomized Controlled Trials Evaluating the Use of Platelet-Rich Plasma for Knee Osteoarthritis: Adherence to Minimum Information for Studies Evaluating Biologics in Orthopaedics.. The American journal of sports medicine, 2025. DOI: 10.1177/03635465241249996.

9. A 2025 review of mesenchymal stem cell injection research in orthopaedics identified 449 registered clinical trials, of which only 159 (35.4%) were complete and only 56 (12.5%) had published results in peer-reviewed journals. Hip and knee osteoarthritis were the most common indications (37.6%). Reported cell concentrations spanned three orders of magnitude and 55.5% of protocols did not specify a concentration at all.

   Bezuglov E, et al. — Mesenchymal stem cells injections in traumatology and orthopaedics: common practice or still a promising area with many uncertainties?. BMC Musculoskeletal Disorders, 2025. DOI: 10.1186/s12891-025-09123-8.